Literature DB >> 14982760

In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii.

Jimmy Yoon1, Carl Urban, Christian Terzian, Noriel Mariano, James J Rahal.   

Abstract

Eight unrelated clinical Acinetobacter baumannii isolates resistant to all commonly used antibiotics were subjected to three-dimensional checkerboard microtiter plate dilution and time-kill studies at one-fourth of their MICs of polymyxin B, imipenem, and rifampin. Synergy was demonstrated with combinations of polymyxin B and imipenem, polymyxin B and rifampin, and polymyxin B, imipenem, and rifampin. Double combinations of polymyxin B and imipenem and of polymyxin B and rifampin were bactericidal for seven of eight isolates, and triple combinations were bactericidal for all isolates within 24 h. Future clinical studies using double and triple therapy with these antibacterials may provide an effective option against potentially lethal infection due to multiresistant Acinetobacter baumannii.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14982760      PMCID: PMC353107          DOI: 10.1128/AAC.48.3.753-757.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium.

Authors:  P Fernandez-Viladrich; X Corbella; L Corral; F Tubau; A Mateu
Journal:  Clin Infect Dis       Date:  1999-04       Impact factor: 9.079

2.  Polymyxin B-Resistant Acinetobacter baumannii Clinical Isolate Susceptible to Recombinant BPI and Cecropin P1.

Authors:  C Urban; N Mariano; J J Rahal; E Tay; C Ponio; T Koprivnjak; J Weiss
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

Review 3.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

4.  Infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus.

Authors:  C A Wood; A C Reboli
Journal:  J Infect Dis       Date:  1993-12       Impact factor: 5.226

5.  A method for testing for synergy with any number of agents.

Authors:  M C Berenbaum
Journal:  J Infect Dis       Date:  1978-02       Impact factor: 5.226

6.  Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii.

Authors:  E J Giamarellos-Bourboulis; E Xirouchaki; H Giamarellou
Journal:  Diagn Microbiol Infect Dis       Date:  2001-07       Impact factor: 2.803

7.  In vitro activities of nontraditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak.

Authors:  M D Appleman; H Belzberg; D M Citron; P N Heseltine; A E Yellin; J Murray; T V Berne
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

Review 8.  Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary.

Authors:  J W Chow; V L Yu
Journal:  Int J Antimicrob Agents       Date:  1999-01       Impact factor: 5.283

9.  Relationship between beta-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii.

Authors:  Felipe Fernández-Cuenca; Luis Martínez-Martínez; Maria Carmen Conejo; Juan A Ayala; Evelio J Perea; Alvaro Pascual
Journal:  J Antimicrob Chemother       Date:  2003-03       Impact factor: 5.790

10.  Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam.

Authors:  E S Go; C Urban; J Burns; B Kreiswirth; W Eisner; N Mariano; K Mosinka-Snipas; J J Rahal
Journal:  Lancet       Date:  1994-11-12       Impact factor: 79.321

View more
  47 in total

1.  In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli.

Authors:  Carl Urban; Noriel Mariano; James J Rahal
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

2.  A 4-year surveillance of antimicrobial resistance patterns of Acinetobacter baumanni in a university-affiliated hospital in China.

Authors:  Ting Xu; Wenying Xia; Guodong Rong; Shiyang Pan; Peijun Huang; Bing Gu
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

3.  Evaluation of antibiotic combinations against multidrug-resistant Acinetobacter baumannii using the E-test.

Authors:  F A Haddad; K Van Horn; C Carbonaro; M Aguero-Rosenfeld; G P Wormser
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-08       Impact factor: 3.267

4.  Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline.

Authors:  F S Taccone; H Rodriguez-Villalobos; D De Backer; V De Moor; J Deviere; J-L Vincent; F Jacobs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-04       Impact factor: 3.267

5.  In vitro activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii.

Authors:  D W Wareham; D C Bean
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 6.  Global challenge of multidrug-resistant Acinetobacter baumannii.

Authors:  Federico Perez; Andrea M Hujer; Kristine M Hujer; Brooke K Decker; Philip N Rather; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

Review 7.  Polymyxins revisited.

Authors:  David Landman; Claudiu Georgescu; Don Antonio Martin; John Quale
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

8.  In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.

Authors:  Ellen S Moland; David W Craft; Seong-geun Hong; Soo-young Kim; Lucas Hachmeister; Shimon D Sayed; Kenneth S Thomson
Journal:  Antimicrob Agents Chemother       Date:  2008-06-02       Impact factor: 5.191

Review 9.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

10.  Characterization of porin expression in Klebsiella pneumoniae Carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems.

Authors:  Jae H Hong; Cornelius J Clancy; Shaoji Cheng; Ryan K Shields; Liang Chen; Yohei Doi; Yanan Zhao; David S Perlin; Barry N Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.